{"entity":{"id":"haloperidol","kind":"drug","name":"Haloperidol","aka":[],"tldr":"Haloperidol is an antipsychotic medicine used in small doses in palliative care for nausea and vomiting, especially when the bowel is blocked.","summary":"The US label covers psychotic disorders, Tourette's disorder and severe behaviour problems in children. MASCC 2022 suggests haloperidol \"may be an effective anti-emetic in MBO, particularly for complete MBO\" (level IV, grade B), and MASCC/ESMO 2016 names it as an alternative to metoclopramide for nausea in advanced cancer and as the antiemetic to give alongside octreotide in bowel obstruction. The antiemetic use is off-label. The first Haldol NDA was approved on 18 May 1971.","status":"approved","asOf":"2026-11-11","wikipedia":"https://en.wikipedia.org/wiki/Haloperidol","links":[{"label":"US label (DailyMed): haloperidol tablets","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00bb61c8-db35-4c04-9ef7-47d447d2496b"},{"label":"Davis et al., MASCC recommendations for the management of malignant bowel obstruction in advanced cancer (Support Care Cancer 2022)","url":"https://doi.org/10.1007/s00520-022-06889-8"},{"label":"Walsh et al., 2016 updated MASCC/ESMO consensus recommendations: management of nausea and vomiting in advanced cancer (Support Care Cancer 2017)","url":"https://doi.org/10.1007/s00520-016-3371-3"}],"tags":["supportive","generic","supportive-care-gaps-2026-11"],"related":["metoclopramide","levomepromazine"],"cancers":[],"sections":[],"technologies":["antiemetic-therapy","palliative-care"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo supportive care gap fill (DailyMed, openFDA, Drugs@FDA, emc SmPCs, NICE, ESMO, ASCO, MASCC, SITC, ASTCT, ITAC, Europe PMC)","editedOn":"2026-11-11"},"brand":"Haldol","modality":"Butyrophenone antipsychotic, used as an antiemetic","supportive":true,"mechanism":"A butyrophenone dopamine antagonist.","approvals":[{"region":"US","year":1971,"indication":"Psychotic disorders; Tourette's disorder; severe behaviour problems in children","note":"Year is the Haldol NDA 015923 approval (Drugs@FDA)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/haloperidol/","neighbours":{"drug":[{"id":"hyoscine","kind":"drug","name":"Hyoscine (scopolamine): butylbromide and hydrobromide","route":"/drugs/hyoscine/"},{"id":"levomepromazine","kind":"drug","name":"Levomepromazine","route":"/drugs/levomepromazine/"},{"id":"metoclopramide","kind":"drug","name":"Metoclopramide","route":"/drugs/metoclopramide/"}],"technology":[{"id":"antiemetic-therapy","kind":"technology","name":"Antiemetics for chemotherapy-induced nausea and vomiting","route":"/technologies/antiemetic-therapy/"},{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/"}]}}